Paper Details

  1. Home
  2. Paper Details

Modified regimen intrapleural alteplase with pulmozyme in pleural infection management: a tertiary teaching hospital experience.

Author: Abdul HamidMohamed Faisal, BanAndrea Yu-Lin, CheongXiong Khee, GhanSheah Lin, NgBoon Hau, Nik AbeedNik Nuratiqah, Nik FuadNik Farhan, Nik IsmailNik Azuan, Syed ZakariaSyed Zulkifli

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study aimed to assess the effectiveness and safety of a modified intrapleural fibrinolysis therapy (IPFT) regimen for complex pleural infection. The modified regimen involved administering 16mg of alteplase (t-PA) with 5mg of DNase over 24 hours, compared to the previous regimen of 10mg t-PA with 5mg DNase twice daily for 72 hours. The study explores a potentially more efficient and effective treatment approach for complex pleural effusions.
Paper Details　
Original Abstract of the Article :
Current management of poorly draining complex effusions favours less invasive image-guided placement of smaller tubes and adjunctive intrapleural fibrinolysis therapy (IPFT). In MIST-2 trial, intrapleural 10 mg alteplase (t-PA) with 5 mg of pulmozyme (DNase) twice daily for 72 h were used. We aimed ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115979/

データ提供：米国国立医学図書館（NLM）

A New Oasis for Pleural Infection Management: Modified Regimen with Alteplase and Pulmozyme

The world of pleural infections is a complex and challenging one, often leaving patients struggling with persistent and debilitating symptoms. This research explores a new approach to managing these infections, focusing on the use of a modified regimen of intrapleural alteplase (t-PA) and pulmozyme (DNase). The researchers evaluated the effectiveness and safety of this approach in patients with complex pleural infections. The study found that the modified regimen, which involved a higher dose of t-PA administered over a shorter period of time, showed promising results, potentially offering a new avenue for treatment.

A Brighter Future: A More Effective and Safer Approach

This study suggests that the modified regimen of intrapleural alteplase and pulmozyme holds great promise for improving the management of complex pleural infections. The researchers found that the modified regimen was not only effective in reducing the size of the pleural effusion, but also well tolerated by patients. The study findings provide a glimmer of hope for patients struggling with these persistent infections, offering a potential solution that is both more effective and safer.

A Camel's Guide to Pleural Infection Management

This study highlights the importance of staying informed about the latest advancements in the treatment of pleural infections. Patients should discuss their treatment options with their healthcare providers and consider participating in clinical trials to contribute to ongoing research. The study findings offer a beacon of hope for patients seeking more effective and less invasive approaches to managing pleural infections.

Dr.Camel's Conclusion

This research represents a significant step forward in the management of pleural infections, potentially offering a new oasis in the vast desert of medical challenges. The study findings encourage continued research to further refine and optimize this promising treatment approach.

Date :
  1. Date Completed 2022-05-19
  2. Date Revised 2022-11-24
Further Info :

Pubmed ID

35581627

DOI: Digital Object Identifier

PMC9115979

Related Literature

Article Analysis
・Effects of dornase alfa
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.